Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Short-term Investments (2020 - 2025)

Protalix BioTherapeutics has reported Short-term Investments over the past 6 years, most recently at $15.6 million for Q4 2025.

  • Quarterly results put Short-term Investments at $15.6 million for Q4 2025, up 3.47% from a year ago — trailing twelve months through Dec 2025 was $15.6 million (up 3.47% YoY), and the annual figure for FY2025 was $15.6 million, up 3.47%.
  • Short-term Investments for Q4 2025 was $15.6 million at Protalix BioTherapeutics, down from $15.7 million in the prior quarter.
  • Over the last five years, Short-term Investments for PLX hit a ceiling of $50.6 million in Q1 2021 and a floor of $5.1 million in Q4 2022.
  • Median Short-term Investments over the past 5 years was $16.1 million (2022), compared with a mean of $21.3 million.
  • Biggest five-year swings in Short-term Investments: tumbled 73.46% in 2022 and later surged 312.82% in 2023.
  • Protalix BioTherapeutics' Short-term Investments stood at $38.0 million in 2021, then plummeted by 86.67% to $5.1 million in 2022, then skyrocketed by 312.82% to $20.9 million in 2023, then fell by 27.98% to $15.1 million in 2024, then increased by 3.47% to $15.6 million in 2025.
  • The last three reported values for Short-term Investments were $15.6 million (Q4 2025), $15.7 million (Q3 2025), and $15.5 million (Q2 2025) per Business Quant data.